Exencial Wealth Advisors LLC Makes New Investment in McKesson Corporation $MCK

Exencial Wealth Advisors LLC bought a new position in McKesson Corporation (NYSE:MCK) in the 4th quarter, Holdings Channel reports. The firm bought 723 shares of the company’s stock, valued at approximately $593,000.

Other hedge funds have also made changes to their positions in the company. J.W. Cole Advisors Inc. lifted its holdings in shares of McKesson by 35.3% in the 3rd quarter. J.W. Cole Advisors Inc. now owns 5,089 shares of the company’s stock worth $3,931,000 after buying an additional 1,329 shares during the period. Cullen Investment Group LTD. lifted its holdings in shares of McKesson by 550.4% in the 4th quarter. Cullen Investment Group LTD. now owns 4,670 shares of the company’s stock worth $3,811,000 after buying an additional 3,952 shares during the period. Private Wealth Partners LLC lifted its holdings in shares of McKesson by 5.6% in the 3rd quarter. Private Wealth Partners LLC now owns 31,841 shares of the company’s stock worth $24,598,000 after buying an additional 1,682 shares during the period. AlphaQuest LLC lifted its holdings in shares of McKesson by 91.2% in the 3rd quarter. AlphaQuest LLC now owns 1,767 shares of the company’s stock worth $1,365,000 after buying an additional 843 shares during the period. Finally, Envestnet Asset Management Inc. lifted its holdings in shares of McKesson by 12.4% in the 3rd quarter. Envestnet Asset Management Inc. now owns 330,647 shares of the company’s stock worth $255,438,000 after buying an additional 36,451 shares during the period. 85.07% of the stock is currently owned by hedge funds and other institutional investors.

McKesson News Summary

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: McKesson sold its stake in Medical‑Surgical Solutions, a move that could unlock cash and simplify the company’s portfolio — potentially supporting buybacks or redeployment of capital. McKesson sells stake in Medical-Surgical Solutions
• Positive Sentiment: McKesson Canada secured national distribution for naturemary, expanding reach into thousands of pharmacies — a small but constructive revenue/market-access win in consumer and retail channels. naturemary Secures National Distribution with McKesson Canada, Unlocking Access to Thousands of Pharmacies
• Positive Sentiment: McKesson put a new $5.0 billion senior unsecured revolving credit facility in place, strengthening liquidity and debt flexibility ahead of potential strategic investments or cash-return programs. McKesson Secures New $5 Billion Revolving Credit Facility
• Neutral Sentiment: Analysts are re‑weighing McKesson’s valuation relative to its biosimilars/co‑manufacturing optionality; fair value estimates moved only marginally, but individual price targets diverge — highlights evolving thesis but no consensus catalyst yet. How The Narrative On McKesson (MCK) Is Shifting Around Biosimilars And Valuation Premium
• Neutral Sentiment: Investor pieces pitching McKesson as a way to play GLP‑1 channel growth highlight upside scenarios but are speculative and unlikely to move fundamentals immediately. GLP-1 trade? McKesson is your stock, this investor says
• Neutral Sentiment: Reports that lawmakers have been increasing holdings in McKesson attracted press attention — notable for optics but not a direct operational driver. Lawmakers increase stakes in McKesson, Boeing, Alphabet amid scrutiny
• Negative Sentiment: Market coverage noted McKesson fell more steeply than the broader market today, reflecting investor selling pressure and concerns over the stock’s premium to historical averages. McKesson (MCK) Falls More Steeply Than Broader Market: What Investors Need to Know
• Negative Sentiment: Competitor coverage (William Blair initiating Cardinal Health at Outperform) highlights investor appetite for distributor exposure elsewhere, which could pressure McKesson’s multiple if flows shift to peers. William Blair Initiates Cardinal Health at Outperform: Is the Pharma Distributor a Stealth Compounder?

McKesson Price Performance

Shares of NYSE:MCK opened at $823.68 on Thursday. The business’s 50-day moving average is $897.30 and its 200 day moving average is $859.47. McKesson Corporation has a 1 year low of $637.00 and a 1 year high of $999.00. The firm has a market capitalization of $100.89 billion, a P/E ratio of 23.69, a P/E/G ratio of 1.20 and a beta of 0.42.

McKesson (NYSE:MCK) last announced its earnings results on Wednesday, February 4th. The company reported $9.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $9.19 by $0.15. McKesson had a negative return on equity of 338.97% and a net margin of 1.09%.The company had revenue of $106.16 billion for the quarter, compared to analyst estimates of $105.98 billion. During the same period in the prior year, the company posted $8.03 EPS. The firm’s quarterly revenue was up 11.4% compared to the same quarter last year. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. On average, analysts expect that McKesson Corporation will post 39.02 EPS for the current year.

McKesson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 1st. Stockholders of record on Monday, June 1st will be issued a $0.82 dividend. The ex-dividend date of this dividend is Monday, June 1st. This represents a $3.28 dividend on an annualized basis and a dividend yield of 0.4%. McKesson’s dividend payout ratio is currently 9.43%.

Wall Street Analyst Weigh In

Several research firms have recently commented on MCK. Mizuho boosted their price target on McKesson from $880.00 to $885.00 and gave the stock a “neutral” rating in a research report on Thursday, February 5th. TD Cowen upped their price objective on McKesson from $1,000.00 to $1,012.00 and gave the stock a “buy” rating in a research note on Thursday, February 5th. Wells Fargo & Company upped their price objective on McKesson from $914.00 to $925.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 5th. JPMorgan Chase & Co. upped their price objective on McKesson from $983.00 to $1,107.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 10th. Finally, Raymond James Financial set a $970.00 price objective on McKesson in a research note on Thursday, March 5th. Fourteen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, McKesson has a consensus rating of “Moderate Buy” and a consensus target price of $972.27.

Insider Transactions at McKesson

In other news, CAO Napoleon B. Rutledge, Jr. sold 328 shares of the stock in a transaction dated Friday, February 6th. The stock was sold at an average price of $955.00, for a total value of $313,240.00. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Leann B. Smith sold 190 shares of the stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $945.00, for a total value of $179,550.00. Following the completion of the transaction, the executive vice president directly owned 2,989 shares in the company, valued at $2,824,605. This represents a 5.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 3,592 shares of company stock valued at $3,518,555 over the last three months. Company insiders own 0.08% of the company’s stock.

About McKesson

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.